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Abstract: Colorectal cancer (CRC) continues to be one of the most common cancers globally.
The incidence has increased in developing countries in the past few decades, this could be partly
attributed to aging populations and unhealthy lifestyles. While the treatment of CRC has seen
significant improvement since the advent of target-specific therapies and personalized medicine,
CRC is oftentimes detected at late or advanced stages, thereby reducing the efficacy of treatment.
Hence, screening for early detection is still the key to combat CRC and to increase overall survival
(OS). Considering that the field of medical diagnostics is moving towards molecular diagnostics,
CRC can now be effectively screened and diagnosed with high accuracy and sensitivity. Depending
on the tumor genotype and genetic profile of the individual, personalized treatments including
tyrosine kinase inhibitor therapy and immunotherapy can be administered. Notably, there can be no
one single treatment that is effective for all CRC patients due to the variation in tumor genetics, which
highlights the importance of molecular diagnostics. This review provides insights on therapeutic
modalities, molecular biomarkers, advancement of diagnostic technologies, and current challenges in
managing CRC.
Keywords: colorectal cancer; molecular; diagnostics; biomarker; technologies; personalized medicine;
therapy; genetic; screening; challenges
1. Colorectal Cancer (CRC) and Its Treatment
Colorectal cancer (CRC) is one of the most common cancers worldwide, ranking third and second
for men and women, respectively. In 2018, Global Cancer Observatory (GLOBOCAN) estimated more
than 1.8 million new CRC cases worldwide [1]. There are various therapeutic modalities for CRC
depending on the pathological characteristics of the tumor. Laparoscopic surgery is normally carried
out for early-stage primary disease, open surgery tumor resection for cases with metastases, and
adjuvant radiotherapy for nonresectable cases. Other CRC therapies are neoadjuvant and palliative
chemotherapies [2,3], immunotherapy [4], and tyrosine kinase inhibitor (TKI) therapy [5]. The advent
of checkpoint inhibitors made of monoclonal antibodies (mAbs) have been a breakthrough for the
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treatment of several cancers including CRC [6]. The safety profile and its efficacy in treating certain CRC
patient populations have led to multiple clinical trials. Figure 1 summarizes the list of CRC treatments
reviewed according to their date of application or approval by the Food and Drug Administration
(FDA) [7–17]. Despite advances in medical and surgical treatment, the long-term survival rates have
not improved much [18]. One of the ways in which CRC can be treated optimally is through the
elucidation of individual genetic profiles for personalized therapies or precision medicine. Since
CRC has several tumor subtypes with complex mutations and genetic variations, treatment decision
supported by molecular testing results can dramatically improve the survival rate [19]. The details and
specifications of the genes will be discussed in the next section. With advancement of DNA sequencing
technologies such as next-generation sequencing (NGS), it is optimistic that precision medicine may
be more accessible and affordable, thereby improving clinical outcomes. The sub-sections below will
discuss the current treatment methods for CRC.
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olecular bio arker is an u brella ter for all bio arkers that can be easured based on the
bio arker’s olecular characteristic. The detection of biomarkers has been the backbone for screening
and diagnostic aid in medical laboratories. They are routinely carried out using patient samples
such as tissue biopsy, blood, urine, and other biological samples. One of the most com on detection
methods used in clinical laboratories is immunohistoche istry (IHC), which detects cellular markers
and phenotypes specific to certain diseases through staining with highly specific antibodies [20]. Since
IHC can be done on both fresh and formalin-fixed tissues, it serves as a convenient, simple, and
cost-effective platform for clinical diagnostics [21]. However, there are several limitations. Although it
is not difficult to obtain commercially produced antibodies, there are no standard guidelines for the
validation of these antibodies. The interpretation of the slides by pathologists can vary considerably
and is affected by how the tissue was processed, stored, and handled. This is exacerbated by the
presence of intratumoral biomarker heterogeneity that can cause discordance in the classification of
cancer [22]. Furthermore, the lack of standardized guidelines for quantitative and semiquantitative
scoring raises concern, especially when it involves clinical decisions. While the American Society
of Clinical Oncology (ASCO) and College of American Pathologists (CAP) issued guidelines for
the handling of biopsy tissues of breast cancer patients, guidelines for other specimens were not
available [23]. At present, most of the emerging biomarkers for CRC are more sensitive and specific as
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they interrogate the disease down to the DNA and RNA level [24]. The sub-sections below will discuss
examples of common and potential biomarkers in CRC.
2.1. Methylated Septin9 (mSEPT9)
Screening programs for CRC are highly effective [25] as most CRCs develop from premalignant
lesions such as adenomas [26]. Traditional screening methods such as fecal occult blood test (FOBT) and
fecal immunochemical test (FIT) are routinely used to screen CRC, but are generally low in sensitivity
and specificity [27]. Currently, the screening of CRC-related biomarkers such as carcinoembryonic
antigen [28] and insulin-like growth factor-1 [29] through liquid biopsy is made more convenient,
but still lacks specificity. Thus, efforts were made to detect tumor-specific DNA in the form of circulating
free DNA (cfDNA). cfDNA is continuously shed by healthy and tumor cells into the bloodstream and
can reflect the entire tumor genome. Methylated Septin 9 (mSEPT9) DNA is the only FDA-approved
methylated biomarker for the screening of CRC through the detection of cfDNA in the serum of CRC
patients [30,31]. Warren et al. evaluated the FDA-approved mSEPT9 kit (Epigenomics AG, Germany)
and reported an overall sensitivity and specificity in all CRC stages at 90% and 88%, respectively.
In early stages of cancer (I and II), the test was 87% sensitive. False-positive rate was reported at 12%.
mSEPT9 can be detected in precancerous lesions such as colorectal adenomas [18], but may not be
reliably sensitive [32]. In a small prospective study, mSEPT9 was detected in 12% of adenomas with a
false-positive rate of 3% [18]. From the year 2012 onwards, more studies were pointing toward the
reliability of detecting mSEPT9 for CRC screening, with sensitivities ranging from 73% to 95.6% [33–37].
The heterogeneity of the sensitivities is likely affected by non-neoplastic factors including, but not
limited to, demographics, methodology, lifestyle, and sex [37]. Asides from CRC, SEPT9 may also be
involved in the tumor progression of leukemia [38], breast [39], ovarian [40], urologic [41], and brain
cancers [42]. Nevertheless, the detection of mSEPT9 as cfDNA for CRC has been proven to be effective
and should be considered to be included as a routine screening test for CRC.
The role of mSEPT9 in the screening of CRC is well established, but its prognostic role remains
unclear. A recent study by Ma and co-workers linked higher levels of mSEPT9 in post-surgery CRC
patients to higher cancer recurrence [43]. If validated by future studies, the same FDA-approved kit
can be conveniently used in both screening and prognostic tests without extensive optimizations.
Similar to mSEPT9, hypermethylations of other DNA biomarkers are also being investigated for their
potential role in CRC screening [44]. Methylated DNA are ideal biomarkers for screening as epigenetic
alterations occur very early in polyp-to-cancer progression [45]. In addition, there is a plethora of other
potential CRC biomarkers in the form of cfDNA that are being studied [46], but will not be reviewed
due to space constraints.
2.2. Microsatellite Instability (MSI)
Microsatellite instability (MSI) is described as having genes with altered lengths due to small
insertions and deletions of short, repetitive DNA sequences throughout the genome [47,48]. These
mutations are normally found in the coding single nucleotide repeats of tumor suppressor genes such
as activin receptor type 2 and transforming growth factor βR2 [49]. Approximately 15% of all CRC
cases are MSI, and patients with MSI-high (MSI-H) have a better prognosis in terms of longer overall
survival (OS) and lower metastatic rate, but the tumors are more resistant to adjuvant chemotherapy
such as 5-fluorouracil (5-FU) [50]. While MSI-H patients have been shown to be unresponsive to 5-FU,
a meta-analysis by Jover et al. found that DNA mismatch repair (MMR) mutational status should
not be indicative of chemotherapy efficacy [51]. MSI status by itself is also predictive for treatment
response to the anti-programmed cell death 1 (PD-1) checkpoint inhibitor pembrolizumab in metastatic
CRC (mCRC) patients. Pembrolizumab is only effective in mCRC patients with MSI-H status [52,53].
The exact interactions and mechanisms between checkpoint inhibitors and MSI status are currently
unknown, but its approval by the FDA for the treatment of MSI-H solid tumors is based on several
successes in clinical trials, as summarized by Marcus et al. The approval of pembrolizumab marks the
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first time in history a drug was approved solely based on a common molecular marker instead of the
primary site of origin [7]. Recently, however, tumor mutational burden (TMB) is seen as a superior
predictive marker over MSI status. TMB is measured in number of mutations/megabase (mut/MB).
This was shown in a study by which anti-PD-1 immunotherapy was effective in microsatellite stable
(MSS) CRC tumors with high TMB (≥10 mut/MB) [54]. Contrary to other studies demonstrating the
lack of efficacy of anti-PD-1 therapy in MSS patients, the importance of TMB over MSI status needs to
be investigated further.
2.3. KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog)
The significance of (KRAS) Kirsten rat sarcoma viral oncogene homolog mutational profile as a
negative predictive biomarker in the treatment response of mCRC using monoclonal antibody (mAb)
against epidermal growth factor receptor (EGFR) is well established [55–57]. Clinical trials such as
PRIME (panitumumab) and CRYSTAL (cetuximab) demonstrated positive response towards anti-EGFR
mAb therapies only in wild-type (WT) KRAS mCRC patients. This is because KRAS activation in
KRAS-mutated mCRC patients is independent of upstream EGFR activation [58,59]. A subsequent
retrospective study by the FDA on seven randomized trials resulted in the approval of cetuximab and
panitumumab only in WT KRAS mCRC patients [3,10]. Previously, KRAS mutation was identified only
by mutations in Codon 12 and 13 of Exon 2, which was subsequently found to be insufficient for an
accurate prediction of treatment response [60]. Thus, the CRC clinical guideline urges for extended
RAS mutation testing including KRAS and (NRAS) neuroblastoma RAS viral oncogene homolog in exon 2
(codons 12 and 13), exon 3 (codon 59 and 61), and exon 4 (codon 117 and 146) [19].
2.4. BRAF (v-raf Murine Sarcoma Viral Oncogene Homolog B1)
BRAF (v-raf murine sarcoma viral oncogene homolog B1) mutation occurs in 10% of CRC cases,
with most of the mutations being presented in Codon 600 [61]. Recent evidences suggest that BRAF
mutation is a better predictor for the determination of anti-EGFR therapy responses than RAS status.
This is exemplified by the lower overall response rate (ORR) of anti-EGFR mAb in mutant BRAF
compared with mutant Exon 2 KRAS [62]. Additionally, BRAF mutation is associated with the promoter
methylation of an MMR gene, MLH1 (human mutL homolog 1), where a positive BRAF mutation is
normally accompanied with negative MMR mutation status. The negative mutation status of MMR
is important for the prediction of MSI status [63,64]. In essence, patients with BRAF mutations are
normally MSS, and are thus less likely to benefit from pembrolizumab treatment. BRAF mutation may
also indicate poor prognosis in CRC patients [65], but is only demonstrated in BRAF-mutated patients
with MSS status, as reported by Roth et al. The study showed that BRAF mutations hold no prognostic
significance in patients with MSI-H [66]. In contrast, a recent meta-analysis of 1164 nonmetastatic
CRC patients with MSI-H showed that BRAFV600E mutation does indicate poor prognosis in terms of
OS [67]. Whilst the mutational testing of BRAF is recommended in the CRC clinical guidelines for
prognostic stratification, and MMR status identification, findings suggest that BRAF mutation alone is
insufficient for a full diagnosis of CRC [19].
2.5. Other Potential Biomarkers
The complex genetic nature and heterogeneity of CRC necessitate the detection of a combination
of biomarkers for a more accurate diagnosis. Thus, efforts are continuously made to validate additional
CRC biomarkers. The sub-sections below will review CRC biomarkers that may potentially be
incorporated into routine clinical diagnostics.
2.5.1. Programmed Death-Ligand 1 (PD-L1)
Programmed Death-Ligand 1 (PD-L1) expression is potentially predictive for the treatment
response of pembrolizumab since high PD-L1 expression has been associated with MSI-H status [68,69].
The association between high PD-L1 expression and MSI-H status has, however, been contrasted in
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another study involving a larger cohort of almost 1,500 samples [70]. It is speculated that these large
variations could be attributed to the difference in immunohistochemistry staining methods and scoring
criteria due to the spatial and temporal heterogeneity of PD-L1 expression in mCRC patients [71].
Another study concluded that the effectiveness of the checkpoint inhibitor appears to be independent
of PD-L1 expression level by tumor cells [72]. Collectively, it is evident that these limitations will
need to be addressed before any clinical applications involving PD-L1 expression can be applied on
CRC patients.
2.5.2. Phosphatidylinositol-4,5-bisphosphate 3-kinase, Catalytic Subunit Alpha (PIK3CA)
PIK3CA mutation has been studied for CRC treatment [73]. It is indicated that the PIK3CA exon
20 mutation confers resistance against anti-EGFR mAb therapy in CRC patients. The response rate (RR)
was reported to be as low as 0%, together with shorter progression-free survival (PFS) [74]. Conversely,
another study demonstrated that PIK3CA did not significantly affect resistance against cetuximab [75].
An independent lab-developed test detecting H1047R and E545K mutations showed sensitivities of 5%
and 10% mutant allele fractions, respectively [76].
2.5.3. Phosphatase and Tensin Homolog (PTEN)
Another biomarker proposed to have predictive and prognostic potential in CRC treatment is
Phosphatase and Tensin Homolog (PTEN) [77]. A study with 67 CRC patients demonstrated that 100% of
the patients with negative expression of PTEN exhibited disease progression following treatment with
cetuximab, whereas 30% of the PTEN expression patients showed reduced disease progression [78].
Nevertheless, a study of a larger cohort found that it was not associated to the RR [79]. Another study
showed that the negative expression of PTEN only negatively correlates to cetuximab response in
tumor metastases but not primary tumor of CRC [80]. Interestingly, some studies showed promising
results where PTEN gene alterations resulted in largely poor OS [81,82], while other findings showed
no correlation between patients’ survival with changes in PTEN expression [83,84]. Together, the
credibility of PTEN as a potential predictive and prognostic marker cannot be determined as of current,
and further investigations need to be carried out.
2.5.4. Human Epidermal Growth Factor Receptor 2 (HER2)
Human Epidermal Growth Factor Receptor 2 (HER2) is a proto-oncogene in the EGFR family
that is mostly known for its oncogenic role in breast cancer [85]. In rare cases, HER2 is amplified in
approximately 5% of mCRC patients with WT KRAS exon 2. This gene exhibits a high concordance
rate in both primary and metastatic tumors of CRC [86] and is mutually exclusive with mutations to
NRAS, KRAS, and BRAF [87]. The amplification of HER2 in relation to anti-HER2 treatment response
in mCRC patients was evaluated by the phase II HERACLES trial combining two anti-HER2 drugs,
trastuzumab and lapatinib. The results of the trial suggested that HER2 amplification may have a
potential role as a clinical predictive marker for CRC, but the extreme rarity of this genetic alteration
proves challenging for the validation of these results in a phase III clinical trial [88].
2.5.5. Micro-RNA (miRNA)
MiRNAs as biomarkers have received increasing attention recently for their predictive, diagnostic,
and prognostic roles in CRC [89]. There are several miRNAs that are of importance to CRC. MiR-135a
and miR-135b, for example, contribute to the regulation of the Wnt/Wingless pathway through the
downregulation of APC (Adenomatous polyposis coli) gene [90] and can potentially act as prognostic
markers [91,92]. Additionally, miR-17-3p and miR-92a (pooled sensitivity, 76%, specificity, 64%) can
upregulate the cell proliferation of colon cancer cells and have been found to be elevated in the plasma
and CRC tissues [93–95]. MiR-211, on the other hand, can act as a marker for both the diagnosis
and prognosis of CRC [96], while miR-133a can be potentially used in predicting response to EGFR
inhibitors [97].
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2.5.6. Consensus Molecular Subtypes (CMS)
Recently, the possibility for the consensus molecular subtypes (CMS) of CRC to be used as
biomarkers was explored. The subtypes are grouped into four based on the tumor gene expression
pattern and are described as: (1) CMS1—strong immune activation, hypermutated, and MSI-H;
(2) CMS2—epithelial and canonical with marked WNT and MYC signaling; (3) CMS3—epithelial with
evident metabolic dysregulation; and (4) CMS4—mesenchymal with stromal invasion, angiogenesis
and prominent transforming growth factor-β activation [98,99]. Prognostic and predictive values
of CMS in mCRC patients independent of cancer staging were evaluated in multiple retrospective
analysis. Collectively, CMS was shown to be significantly associated to lower OS and PFS. In terms of
OS, CMS1 was associated to worst outcome in contrast to CMS2. Notably, positive drug response to
bevacizumab and cetuximab was demonstrated specifically in CMS1 and CMS4, respectively. [100–103].
Significant correlations with known CRC biomarkers such as MSI-H, KRAS, and BRAF mutations were
also reported [100]. A simplified summary of the biomarkers reviewed in Sections 2.1–2.4 is presented
in Figure 2 [18,19,43,54,56,57,70,74,78,79,88,91–94,96,97,100–105].
Diagnostics 2019, 9, x FOR PEER REVIEW 6 of 21 
 
ece tly, t e ossibility for t e co se s s olec lar s bty es ( S) of  to be se  as 
bio arkers as ex lore . e s bty es are gro e  i to fo r base  o  t e t or ge e ex ressio  
atter  a  are described as: (1) CMS1—strong im une activation, hypermutated, and MSI-H; (2) 
CMS2—epithelial and cano ical with marked WNT and MYC signaling; (3) S3 e it elial it  
e i e t eta olic sre latio ; a  (4) S4 ese c al it  stro al i asio , a io e esis 
a  r i e t tra sf r i g gro th factor-β activation [98,99]. Prognostic and predictive values of 
CMS in mCRC patients independent of cancer staging were evaluated i  lti le retr s ecti e 
a al sis. llecti el , C S was shown to be significantly associated to lower OS and PFS. In terms 
of OS, CMS1 was associated to worst outcome in contrast to CMS2. Notably, positive drug response 
to bevacizumab and cetuximab was demonstrated specifically in CMS1 and CMS4, respectively. 
[100–103]. Significant correlati ns with known CRC biomarkers such as MSI-H, KRAS, and BRAF 
mutations were also reported [100]. A simplified su mary of the biomarkers reviewed in Sectio  2.1 
to 2.4 is presented in Figure 2 [18,19,43,54,56,57,70,74,78,79,88,91–94,96,97,100–105]. 
 
Figure 2. Simplified summary of CRC biomarkers. Green arrows represent biomarkers that have more 
than one role. Biomarkers colored in red are potential CRC biomarkers that require additional 
validations. BRAF- v-raf murine sarcoma viral oncogene homolog B1; FIT- fecal immunochemical test; 
CMS- consensus molecular subtypes; EGFR- epidermal growth factor receptor; FOBT- fecal occult 
blood test; HER2- human epidermal growth factor receptor 2; KRAS- Kirsten rat sarcoma viral 
oncogene homolog; miR- microRNA; MLH1- human mutL homolog 1; mSEPT9- methylated Septin 
9; MSH2- human mutS homolog 2; MSI- Microsatellite instability; PD-L1- Programmed death-ligand 
1; PIK3CA- phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha; PMS2- PMS1 
homolog 2, mismatch repair system component; PTEN- Phosphatase and tensin homolog; TMB- 
tumor mutational burden. 
3. Current Molecular Diagnostic Technologies 
With advancements in technology, major progress has been made in understanding how 
variations in the genetic alterations of CRC can contribute toward clinical management. These 
advances have led to the development of precision medicine, which offers individualized medical 
care based on the patient’s personal information and unique genetic profile. This concept has been 
proven to be successful in improving clinical outcomes compared with the relatively conventional 
method of indiscriminate radio/chemotherapy [106]. In fact, the list of drugs targeting specific genetic 
Simplified su mary of CRC biomarkers. Green arrows represent biomarkers that hav
more than n role. Biomarkers colored in red are potential CRC biomarkers that r ir
BRAF- v-raf murine sarcoma viral oncog ne h molog B1; FIT- fecal immunochemical
test; CMS- consensus molec lar subtypes; EGFR- epidermal growth factor receptor; FOBT- fecal
occult blood test; HER2- human pidermal growth factor receptor 2; KRAS- Kirsten rat sarc a
; l ; i lli i ili ; li
; I - ti li it l- , - i t - i , t l ti it l ; -
l 2, mismatch repair system component; PTEN- Phosphatase and te sin homolog; TMB- tumor
mutational burden.
3. Current Molecular Diagnostic Technologies
With advancements in technology, major progress has been made in understanding how variations
in the genetic alterations of CRC can contribute toward clinical management. These advances have
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led to the development of precision medicine, which offers individualized medical care based on the
patient’s personal information and unique genetic profile. This concept has been proven to be successful
in improving clinical outcomes compared with the relatively conventional method of indiscriminate
radio/chemotherapy [106]. In fact, the list of drugs targeting specific genetic alterations approved by
the FDA is rapidly growing for the treatment of advanced-stage solid tumors. Hence, it is important to
understand and appreciate current and developing molecular methods available to diagnose CRC and
the variety of molecular technologies available to map out the individual’s unique molecular profile
for efficient treatment strategies.
Before polymerase chain reaction (PCR) was invented, the detection of nucleic acid biomarkers
was challenging due to scarcity of nucleic acid and tissue heterogeneity in samples. Now, tumor-specific
DNA can be amplified to detectable levels through the more sensitive quantitative PCR (qPCR) [107],
while RNA-based biomarkers such as miRNA can be detected using quantitative reverse transcription
PCR (RT-qPCR) [94]. As technology improves, extremely scarce biomarkers such as tumor-specific
cfDNA can be detected using qPCR, digital PCR, and NGS. Digital PCR is the latest variation of PCR
that has since entered the diagnostic market recently, when detection of very rare events or gene variants
in patient sample is challenging using qPCR. NGS, on the other hand, refers to high-throughput nucleic
acid sequencing platforms using fragmented and PCR-amplified DNA, with performance comparable
to digital PCR in terms of rare event detection [108]. The sub-sections below will discuss updates on
the use of current molecular diagnostic technologies to detect major CRC-related biomarkers such as
KRAS, BRAF, MSI, and so on.
3.1. Detection of KRAS and BRAF Mutations
For CRC, the mutational status of the genes KRAS and BRAF receives additional attention as
they can negatively affect the patient’s response towards anti-EGFR therapies, with the prevalence of
somatic KRAS mutations being 40% [109]. A myriad of molecular assays can detect these mutations
with limit of detections ranging from 10–20% mutant allele for Sanger sequencing [110], around 5% for
pyrosequencing [110,111] and high-resolution melt (HRM) curve analysis [110,112], to 1–5% for qPCR
assays [113,114]. While direct sequencing remains the gold standard for KRAS and BRAF mutations
detection, the method is not popular as it is laborious and lacks sensitivity [106,115].
3.1.1. PCR-Based Detection
Currently, there are several FDA-approved assays for the detection of KRAS and BRAF mutations,
including cobas 4800BRAFV600 mutation assay [116], cobas 4800KRASmutation assay, and therascreen
KRAS assay [117,118]. These assays are FDA-approved for specific samples, but they are not suitable for
use in specimens containing limited tissue such as fine needle aspiration and core biopsy [106]. A study
by Nordgård et al. compared the performance and cost-effectiveness of two relatively new sensitive
molecular methods for the detection of KRAS mutations called amplification refractory mutation
system (ARMS) PCR assay and peptic nucleic acid (PNA) clamp PCR [119]. The ARMS PCR assay is
an allele-specific PCR that detects a specific known mutated form of a gene [47], while the PNA clamp
PCR is capable of selective amplification of nucleic acid sequences that differ by a single base [120].
In comparison, the PNA clamping assay was in favor as it is approximately 20 times cheaper than
ARMS and demonstrated higher sensitivity levels [119]. Another method that utilizes a modified PCR
protocol termed as coamplification at lower denaturation temperature PCR (COLD-PCR) was designed
to detect KRAS and BRAF V600E mutations in combination with HRM. Compared with traditional PCR
and direct sequencing that picked up 57 KRAS/BRAF mutations out of 117 CRC samples, this method
detected 72 KRAS/BRAF mutations, which translates to a 26.3% increase in detection. In addition,
this method does not require time-consuming procedures and expensive equipment. Thus, it can be
considered for diagnostic uses [121].
In respect of technology, many of the available routine molecular tests are heading toward
automation, including EGFR mutation detection. The Idylla (Biocartis, Belgium) is a CE-IVD (CE
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Marking In Vitro Diagnostic for Medical Devices) marked fully-automated qPCR diagnostic platform
for EGFR mutations that is simple to perform (hands-on time of less than 2 min), does not require
molecular expertise to run, is reliable, rapid, and has a small footprint [122]. Its KRAS mutation test
allows the simultaneous detection of 21 mutations in clinically relevant codons (12, 13, 59, 61, 117, and
146) from FFPE (formalin-fixed paraffin-embedded) tissue samples, while its NRAS–BRAF mutation
test can detect codons 12, 13, 59, 61, and 117 for NRAS and V600 mutations for BRAF [123]. Its ease of
use, lack of expertise required to operate the system, and rapid turn-around time allows for the system
to be placed in most clinical settings.
3.1.2. Nucleic Acid Hybridization Assay
There are cost-effective alternatives for the detection of KRAS and BRAF other than qPCR.
This includes single nucleotide primer extension (SNaPshot) assay and reverse hybridization StripAssay.
The SNaPshot is a flexible lab-developed test, while the StripAssay is a commercially available
test [115,124,125]. For KRAS, the detection limits when compared with direct sequencing are 10% and
1%, respectively [115]. In terms of sensitivity and turn-around time, the KRAS StripAssay is more
favorable as it is a rapid and sensitive test that can be utilized when few tumor cells are present.
For BRAF, Magnin et al. demonstrated similar results among SNaPshot, direct sequencing, and
HRM [125]. Evaluation data on the performance of BRAF using the StripAssay is, however, lacking
and warrants further investigation. In short, SNaPshot and the KRAS StripAssay are suitable for
laboratories lacking dedicated equipment, but Sarasqueta et al. has warned for KRAS-mutant to be
confirmed to reduce the risk of false positives [115].
3.1.3. Pre-PCR Isolation of Circulating Tumor Cells (CTCs)
Since it is difficult to obtain sufficient or appropriate tumor samples for KRAS genotyping, an
alternative method is required. Thus, circulating tumor cells (CTCs) have garnered a strong reaction
from researchers and clinicians as they are thought to represent the tumor in real-time. The extremely
low levels of DNA in CTCs can be detected through qPCR with HRM or droplet digital PCR (ddPCR).
When compared, ddPCR was able to detect less than one KRAS mutant cell per mL of neat blood
(0.05% mutant ratio) while qPCR (TaqMeltPCR) and HRM could only detect up to 0.5% mutant
ratio. In addition to its high sensitivity, the noninvasive nature of this procedure also allows for
future opportunities to screen, diagnose, and monitor treatment or relapse in real-time without much
discomfort to the patients [126]. One of the biggest hurdles to downstream analysis of CTCs is the
effective and reliable method of isolating CTCs. There are several commercially available equipment for
the isolation of CTCs through physical and biochemical properties such as size exclusion, deformability,
and surface marker expression, but they are not without challenges. The size, rigidity, and surface
marker expression pattern of CTCs are known to be highly variable. Furthermore, marker-based
isolation of CTCs is only possible on the availability of the particular antibody [127].
3.1.4. Circulating Free DNA (cfDNA) Detection
Moving forward, RAS mutations can now be detected as cfDNA without the need to isolate CTCs.
In a study published in 2018, researchers compared three diagnostic platforms for RAS mutations
detection through cfDNA: ddPCR (Bio-Rad), NGS (Illumina), and BEAMing/OncoBEAM-RAS-CRC
(BEAM, Sysmex Inostics). Tissue biopsies and time-matched blood samples were collected for the
simultaneous comparison of mutation profiles between cfDNA and FFPE. The digital PCR-based
BEAM reached a detection threshold of 0.03%, significantly lower than the detection thresholds of the
two compared platforms at 0.5–1%. The superior sensitivity of the BEAM allowed the detection of
KRAS mutations in 5/19 FFPE profiles shown to be negative. Based on the comparison of sensitivity,
specificity, positive predictive value (PPV), and negative predictive value (NPV) among the three
platforms (Table 1) [108], the BEAM is superior in most aspects, except for the specificity, which is
slightly lower than that of the other two platforms. While the NGS is more suitable for the detection
Diagnostics 2020, 10, 9 9 of 21
of a large coverage of mutations, the results are oftentimes confirmed with ddPCR [108]. In clinical
settings where there is a need to balance the coverage of large mutation profiles with specificity of a
particular mutation, it will be useful to have the BEAM together with the NGS as a complementary
platform. As shown in Table 1, NGS may be a better choice, but the decision on which platform to
select will require the consideration of footprint, cost, and turn-around-time (TAT). Furthermore, the
clinical relevance of detecting mutations at very low allelic frequency was not assessed. While the
results of ddPCR are less informative, it has the shortest TAT of only 8 h for the complete mutational
analysis of KRAS exon 2. The more extensive mutational analysis of KRAS from BEAM and NGS will
require around 2 days and 7 days, respectively. In terms of costing, NGS and the BEAM are comparable
but cost twice as much compared with the ddPCR [108].
Table 1. Comparison of the sensitivity, specificity, PPV (positive predictive value), and NPV (negative
predictive value) of ddPCR, BEAM, and NGS for KRAS detection [108].
Platform Sensitivity (%) Specificity PPV (%) NPV (%)
ddPCR 47 77 70 55
BEAM 93 69 78 90
NGS 73 77 79 71
3.2. Detection of Microsatellite Instability (MSI)/Microsatellite Stable (MSS) Status
Similar to the detection of other biomarkers, MSI can be detected through PCR-based methods
and NGS. The versatility of NGS allows for the simultaneous detection of thousands of different
microsatellite loci with a limit of detection of 1% MSI in MSS background. However, the use of NGS
for MSI detection is uncommon, as data interpretation requires specific algorithms and computational
methods [128]. Notably, MSI can also be detected indirectly through the detection of miRNA biomarkers.
There are several methods in which MSI can be detected. Capillary electrophoresis fragment
analysis is one of the earliest molecular method using PCR-amplified samples, but presents with
a low limit of detection of 1% to 10% [128]. This method usually interrogates epiphenomenon
related to MSI, such as MMR gene loci [129]. The 1997 National Cancer Institute-sponsored MSI
workshop recommends the interrogation of five microsatellite loci; three dinucleotide (D2S123, D5S346,
and D17S250) and two mononucleotide repeats (BAT-25, BAT-26), which led to the development
of the Bethesda panel. This assay amplifies the repeats through a single multiplex PCR reaction,
followed by analysis using capillary electrophoresis. MSI-H is reported when two or more loci are
instable, while instability at a single locus or no instability will be reported as MSI-low and MSS,
respectively. Commercially, Promega Corp developed the MSI Analysis System version 1.1 that detects
five mononucleotide (BAT-25, BAT-26, NR-21, NR-24, and MONO-27) and two pentanucleotide repeats
(PentaC and PentaD). Like the previous assay, capillary electrophoresis is subsequently used for
analysis. MSI-H is reported when two or more mononucleotide loci are instable, while instability at
a single mononucleotide locus represents MSI-low, and no instability represents MSS. Murphy et al.
compared the two assays with 34 CRC patient samples and found that the concordance rate was at 85%.
MSI-H and MSS cases were fully concordant on both assays. While both assays performed adequately
in detecting MSI cases, the authors concluded that the MSI Analysis System was superior and will
be a better option to resolve cases of MSI-low into either MSS or MSI-H [130]. In another study, the
Promega MSI Analysis System version 1.2 was compared to a new “one mononucleotide” MSI marker
test, which detects T25 mononucleotide repeat of the caspase 2 gene (CAT25). The CAT25 MSI test
claims to be a simplified assay with reduced cost and may improve efficiency. Based on the results, the
authors concluded that the CAT25 assay performed equally well to the commercial kit and should
be considered as a replacement to a five markers test, or at least, be included in the MSI detection
panel [131]. Additionally, an MSI gene expression assay with 64 genes has been made available as a
diagnostic assay, which helps to accurately identify MSI-positive and MSI-like patients that are not
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easily recognized by IHC or PCR. Furthermore, this assay does not require a reference paracancerous
tissue from the patient for comparison [65].
3.3. miRNA Detection
MSI status can also be tested through the detection of miRNA biomarkers in the plasma as cell-free
form. One of the methods is through RT-qPCR, which measures the quantity of miRNA indirectly in
real-time [132]. Microarray, which utilizes in situ hybridization of predesigned probes to the target
miRNA is also a reliable method to quantify the amount of miRNA in the sample [133]. An MSI
oligonucleotide microarray diagnostic assay based on spotted locked nucleic acid (LNA) can be used
to profile the expression of up to 315 miRNAs [89]. While RT-PCR and microarray are highly sensitive
and specific, the operational cost is expensive. Dedicated equipment, facilities, and trained personnel
are also required to run these tests [134,135]. Thus, these methods may not be suitable for clinics or
settings with poor resources.
Alternatively, resource-lacking clinical settings may opt for lateral flow nucleic acid strip assay
using gold nanoparticles [135]. This assay has been demonstrated to be more apt as a point-of-care test
as it is sensitive, inexpensive, rapid, and simple to use [135,136]. Similar to the microarray system, this
assay utilizes predesigned probes conjugated to gold nanoparticles targeting specific miRNAs, leading
to the formation of visible bands on the strip [47]. The results are semiquantitative as the intensity of
the band increases with the quantity of the miRNA, but can be made more quantitative with the use of
a quantitative detection platform [135,136]. It was shown that miRNAs can be quantified to as low as
1 fmol, and with the use of silver enhancement, it can be as low as 5 amol [134].
3.4. Detection of Other Biomarkers
In theory, most of the molecular biomarkers discussed other than KRAS, BRAF, and MSI can be
detected using similar diagnostic platforms such as qPCR and NGS. This is shown in several studies
attempting to validate the use of additional biomarkers for CRC diagnostics. A brief summary of CRC
biomarkers and their respective diagnostic platforms from Section 2 and 3 is tabulated in Table 2.
Table 2. Summary of CRC biomarkers and their respective diagnostic platforms reviewed.
Biomarker Diagnostic Platform References
mSEPT9 • Methylation-specific real-time PCR [18]
MSI
• Immunohistochemistry [64]
• Next-generation sequencing (NGS) [89]
• Fragment analysis [128]
• Gene expression assay [130]
• miRNA microarray [89]
TMB • Whole exome sequencing [54]
KRAS
• qPCR (Roche Cobas 4800 KRAS mutation, Qiagen therascreen KRAS,
Biocartis KRAS mutation assay) [117,122]
• Direct sequencing [106]
• Pyrosequencing [111]
• Next-generation sequencing (NGS) [108]
• High-resolution melt curve (HRM) [110]
• Amplification refractory mutation system (ARMS) PCR [119]
• Peptic nucleic acid (PNA) clamp PCR [119]
• COLD-PCR [121]
• Single nucleotide primer extension (SNaPshot) [115]
• Reverse hybridization KRAS StripAssay [115]
• Digital PCR (Bio-Rad droplet digital PCR, Sysmex BEAMing) [108]
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Table 2. Cont.
Biomarker Diagnostic Platform References
BRAF
• qPCR (Roche Cobas 4800 BRAF V600, Biocartis Idylla NRAS-BRAF
mutation assay) [117,122]
• Direct sequencing [106]
• Pyrosequencing [111]
• Next-generation sequencing (NGS) [108]
• High-resolution melt curve (HRM) [110]
• COLD-PCR [121]
• Immunohistochemistry [106]
• Single nucleotide primer extension (SNaPshot) [125]
• Reverse hybridization BRAF StripAssay [124]
miRNA
• Microarray—spotted locked nucleic acid (LNA) [89]
• RT-qPCR [132]
• Lateral flow nucleic acid strip assay using gold nanoparticles [47]
PD-L1 • Immunohistochemistry [68]
PIK3CA
• Real-time PCR [76]
• Immunohistochemistry [73]
• Gene sequencing [73]
HER2
• Immunohistochemistry [86]
• Quantitative reverse transcription PCR (RT-qPCR) [85]
PTEN
• Indirect immunofluorescence [78]
• Immunohistochemistry [77]
CMS • Gene expression microarray [99]
4. Challenges and Limitations
4.1. Choice of Molecular Platform
For cancer diagnosis and screening, accuracy, specificity, and fast TAT should be given critical
attention [137]. qPCR is currently the choice of molecular method for biomarker detection as many tests
are validated and it is more readily available than digital PCR and NGS. In addition, test results can be
available within a day. However, the throughput is limited to several targets, and prior knowledge of the
target DNA is required. Conversely, a single run of NGS is capable of providing invaluable information
including mutations, chromosomal rearrangements, and copy number alterations without any prior
knowledge of the targets [138], although it may take up to 7 days for results to be available [108].
Superior sensitivity, specificity, and throughput must not be the sole reason for the molecular platform
chosen. Instead, consideration must be given to the type of clinical application, cost effectiveness,
and the necessity for superior performance, as it is not possible for all medical settings to incorporate
advanced molecular laboratories. A centralized and highly specialized cancer diagnostic lab will need
to be established in major cities or states to process samples from surrounding clinical settings, but may
have several drawbacks. The need to handle sensitive clinical samples during transportation and
process samples in batches will lead to a longer TAT. Consequently, some critically ill patients may
have to wait for several days or up to weeks before receiving appropriate treatment [19,139].
4.2. Laboratory Operations
Guidelines for CRC molecular testing have been established in a joint effort by the American
Society for Clinical Pathology (ASCP), American Society of Clinical Oncology (ASCO), Association
for Molecular Pathology (AMP), and the College of American Pathologists (CAP). For clinical sample
management and laboratory operations, the recommendations by the guidelines will be summarized
and discussed here. Firstly, policies should be established in all laboratories to ensure efficient allocation
of tissue for molecular tests, especially in scarce specimens. Pathologists can contribute to this by
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evaluating tissue quantity, quality, and malignant tumor cell fraction. Another way is to limit the
number of tissue fragments per individual cassette. Prior assessment of the patients’ previous CRC
status will contribute to unnecessary repeat tests. The usage of appropriate tissue type may also aid in
limiting the wastage of precious tissue; the guidelines recommend using recurrent or mCRC tissues
for predictive biomarker testing involved in cancer treatment given that samples are available and
adequate, followed by primary tumor tissue. For molecular biomarker mutational testing, FFPE tissue
samples are considered acceptable. However, an alteration to the tissue processing protocols or the use
of other specimens (including samples of cytologic origins) necessitates additional validation [19].
Another recommended practice to consider is to provide clinically appropriate turn-around time
(TAT), which will contribute to the alleviation of patient anxiety and the execution of timely patient
management decisions. This can be achieved through the optimal utilization of relevant molecular and
IHC tests, possibly through multiplexed assays. In general, nonacute biomarker test results should
be available within 10 days of test ordering [19,140]. The 10 day timeframe should include the time
taken for test orders to reach the laboratory, tissue block retrieval, and shipment of said blocks to the
performing laboratory. Every effort should be taken by the laboratory to minimize delays in tissue
block retrieval, processing time, and the availability of results [19].
5. Conclusions and Future Perspectives
It is important to understand the epidemiology, etiology, mechanisms, and how to improve
diagnostics and treatment in CRC. Owing to the continuous research of CRC by dedicated researchers,
the mechanisms underlying CRC are now more understood, resulting in extensive diagnostic and
treatment options. Detection of circulating free DNA from liquid biopsy is currently in trend as it
is less invasive and extremely sensitive. Notably, the detection of methylated SEPT9 in the plasma
of CRC patients has been shown to be a reliable screening tool and has been FDA-approved as the
first liquid biopsy screening tool for CRC. These sensitive diagnostic tools will shape how and what
treatments are prescribed, as certain targeted treatments are only effective in certain genotypes of CRC.
Evidently, there will be limitations to the implementation of such tests and treatments in all healthcare
settings. Furthermore, as with all new technology, validation studies and standardization of operations
and methodologies remain a challenge. In essence, CRC continues to be one of the most prevalent
cancers in the world and is mostly detected in advanced stages. Thus, current and future research
should strongly emphasize on early screening of CRC as it is one of the most effective way to prevent
CRC. The future of CRC prevention, diagnostic, and treatment lies in the decentralization of molecular
tests. Currently, extremely sensitive molecular methods for biomarker detection require sophisticated
equipment, facilities, and trained personnel, resulting in the need for centralization and longer TAT.
This necessitates the development of simple, automated, and robust biomarker detection platforms
with smaller footprints.
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Abbreviations
APC Adenomatous polyposis coli
ARMS Amplification refractory mutation system
BRAF B-Raf protein
cfDNA Circulating free DNA
COLD-PCR Coamplification at lower denaturation temperature PCR
CRC Colorectal cancer
CTC Circulating tumor cells
ddPCR Droplet digital PCR
DNA Deoxyribonucleic acid
EGFR Epidermal growth factor receptor
FDA Food and Drug Administration
FFPE Formalin-fixed paraffin embedded
FIT Fecal immunochemical test
FOBT Fecal occult blood test
HER2 Human epidermal growth factor 2
IHC Immunohistochemistry
KRAS Kirten rat sarcoma viral oncogene homolog
LNA Locked nucleic acid
mAb monoclonal antibody
mCRC metastatic colorectal cancer
miRNA microRNA
MMR Mismatch repair
MSI Microsatellite instability
NGS Next-generation sequencing
NRAS Neuroblastoma RAS viral oncogene homolog
ORR Overall response rate
OS Overall survival
PD-L1 Programmed cell death protein ligand 1
PFS Progression-free survival
PNA Peptide nucleic acid
RR Response rate
RT-qPCR Quantitative reverse transcription PCR
SEPT9 Septin 9
TKI Tyrosine kinase inhibitor
TMBWNT Tumor mutational burdenWingless and int-1
WT Wild-type
5-FU 5-fluorouracil
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